Evidence map›Paper›PMID 35588952›Full record

ReviewBiotechnology advances2022

Boosting extracellular vesicle secretion.

Lior Debbi, Shaowei Guo, Dina Safina, Shulamit Levenberg

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biotechnology advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. TEAD1 Enhances Exosome Secretion and Promotes Exosome-Mediated Tissue Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lior DebbiFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Shaowei GuoThe First Affiliated Hospital, Shantou University Medical College, Shantou, China.
Dina SafinaFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Shulamit LevenbergFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: shulamit@bm.technion.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, extracellular vesicles (EVs), specifically exosomes, have emerged as a promising strategy for treating a wide spectrum of pathologies, such as cancer and COVID-19, as well as promoting tissue regeneration in various conditions, including cardiomyopathies and spinal cord injuries. Despite the great potential of EV-based therapies, poor yield and unscalable production of EVs remain big challenges to overcome to translate these types of treatment to clinical practices. Here, we review different strategies for enhancing EV yield by physical, biological or chemical means. Some of these novel approaches can lead to about 100-fold increase in EV production yield, thus bringing closer the clinical translation with regard to scalability and efficiency.

Indexed as

COVID-19ExosomesExtracellular VesiclesNeoplasmsHumansDrug deliveryExosomesExtracellular vesiclesLarge-scale

Identifiers

PMID35588952
PMCPMC9420194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.